Generate Biomedicines (GENB) vs Mesoblast (MESO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Mesoblast is the larger company by market cap ($1.81 billion vs $1.74 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GENB | MESO |
|---|---|---|
| Share price | $13.57 | $13.94 |
| Market cap | $1.74B | $1.81B |
| 1-day change | -1.67% | +2.42% |
| YTD return | — | -22.73% |
| 1-year return | — | -22.94% |
| 5-year return | — | +22.71% |
| Forward P/E | — | 30.64 |
| EPS (TTM) | $-2.40 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.67 | $21.50 |
| 52-week low | $11.00 | $13.05 |
| Distance from 52-week high | -40.14% | -35.16% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +98.97% | +165.42% |
| Average volume | 1.04M | 236.60K |
| Shares outstanding | 128.35M | 129.85M |
| Employees | 312 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
GENB vs MESO FAQ
Which is bigger, Generate Biomedicines or Mesoblast?
Mesoblast (MESO) is larger, with a market capitalization of $1.81B compared with $1.74B for Generate Biomedicines (GENB).
Are Generate Biomedicines and Mesoblast in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Generate Biomedicines and Biotechnology: Biological Products (No Diagnostic Substances) for Mesoblast.